Inflammatory Markers and Level of Cortical Hyperactivity
Launched by UNIVERSITY OF CHILE · Aug 7, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how certain inflammatory markers in the body relate to brain activity in older adults with cognitive disorders, particularly those who may be experiencing early signs of Alzheimer's disease. Researchers are looking to understand how inflammation, indicated by specific proteins in the blood, affects brain activity when patients are given a common anesthetic called propofol during elective surgeries.
To participate in this study, you need to be over 60 years old and scheduled for an elective surgery. It's important that you can understand and agree to participate by signing a consent form. However, if you have any other serious brain conditions, active illnesses, severe mental health issues, or an allergy to propofol, you won't be eligible. If you join the trial, you will undergo some tests to measure your brain's electrical activity while being given propofol, helping researchers learn more about the connections between inflammation and brain function in older adults.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults over 60 years of age undergoing elective surgery
- • 2. Able to understand and sign an informed consent form
- Exclusion Criteria:
- • 1. Diagnosis of other neurological pathologies
- • 2. No active acute or chronic decompensated diseases
- • 3. No severe psychiatric illnesses
- • 4. Propofol allergy
About University Of Chile
The University of Chile, a leading academic institution in South America, is dedicated to advancing medical research and improving public health through innovative clinical trials. With a strong emphasis on collaboration among multidisciplinary teams, the university leverages its extensive resources and expertise to conduct rigorous and ethically sound studies. By integrating cutting-edge scientific methodologies and fostering partnerships with healthcare providers, the University of Chile aims to contribute valuable insights to the medical community and enhance patient care both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Santiago, Rm, Chile
Santiago, Rm, Chile
Patients applied
Trial Officials
Pedro Lobos, PhD
Principal Investigator
University of Chile
Antonello Penna, MD, PhD
Study Chair
University of Chile
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported